Angion Biomedica (ANGN) Stock Price, News & Analysis

Company Overview

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.00 to $10.00
• 52-Week Range: N/A
• Volume: 224,800 shs
• Average Volume: 86,718 shs
• Market Capitalization: $30.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Angion Biomedica Stock Analysis - MarketRank™

Angion Biomedica scored higher than 12% of companies evaluated by MarketBeat, and ranked 899th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Angion Biomedica.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Angion Biomedica are expected to grow in the coming year, from ($1.51) to ($0.53) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ANGN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Angion Biomedica does not currently pay a dividend.

Dividend Growth

Angion Biomedica does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.73

Short Interest

There is no current short interest data available for ANGN.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for ANGN on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Angion Biomedica insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.70% of the stock of Angion Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 17.00% of the stock of Angion Biomedica is held by institutions.

ANGN Stock Analysis - Frequently Asked Questions

How were Angion Biomedica's earnings last quarter?

Angion Biomedica Corp. (NASDAQ:ANGN) issued its quarterly earnings results on Friday, November, 12th. The company reported ($5.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($7.30) by $2.00. The company earned $1.46 million during the quarter, compared to the consensus estimate of $1.08 million.

When did Angion Biomedica's stock split?

Shares of Angion Biomedica reverse split before market open on Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Angion Biomedica IPO?

Angion Biomedica (ANGN) raised $75 million in an initial public offering on Friday, February 5th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Stifel served as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

What other stocks do shareholders of Angion Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Angion Biomedica investors own include Evofem Biosciences (EVFM), Plug Power (PLUG), CNS Pharmaceuticals (CNSP), Viking Therapeutics (VKTX), ContextLogic (WISH), Abeona Therapeutics (ABEO) and Applied Genetic Technologies (AGTC).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 5/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ANGN
• CIK: 1601485
• Web: www.angion.com
• Phone: 415-655-4899
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-38,810,000.00
• Net Margins: N/A
• Pretax Margin: -4,456.97%
• Return on Equity: -47.53%
• Return on Assets: -40.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.00
• Quick Ratio: 20.00

Sales & Book Value

• Annual Sales: $2.30 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.32 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 30,110,000
• Free Float: 24,182,000
• Market Cap: $30.11 million
• Optionable: Not Optionable
• Beta: 0.60